AVBP today
$13.51+$0.02 (+0.11%)close Nov 11, 2026Trend
DailyDowntrend (confirmed)
4 hourStrong Bearish
1 hourBearish
15 minLeaning Bullish
5 minExpanding
Daily trend turns up above $31.49
Key levels
Resistance$17.76
Resistance$15.26
Support$12.00
Latest news & SEC filings
AnalystTruist Securities raises ArriVent BioPharma price target
AnalystTruist Securities keeps Buy rating on ArriVent BioPharma, lifts target to $24
EarningsArriVent BioPharma posts Q3 2026 financials
NewsArriVent BioPharma Announces Executive Retirement
All AVBP news →About ArriVent BioPharma
ArriVent BioPharma is a clinical-stage biopharmaceutical company that develops cancer treatments, concentrating first on solid tumors. Its main candidate, firmonertinib, is an oral EGFR inhibitor being tested in late-stage trials for non-small cell lung cancer involving uncommon EGFR mutations, such as exon 20 insertion and PACC mutations. The company also pursues next-generation ADC therapies, including a CDH17-targeted candidate for gastrointestinal tumors, through licensing deals and research partnerships. It operates in the United States and other countries, while rights to greater China for some programs belong to partners.
Based on the company's 10-K filed Mar 5, 2026.
Nasdaq · Healthcare
ArriVent BioPharma, Inc. (AVBP)
What Is the Price Target for AVBP?
SEPT Low Target
$18.00
SEPT Mid Target
$29.00
SEPT High Target
$30.00
Analyst Consensus
$29.00
Is AVBP a Buy or Sell Right Now?
Thesis
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for AVBP.
Start Free Trial →Is AVBP Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
P/B, Analyst Consensus
Fair Value
$26.74
12
Moat Score
NONE
1/9
Piotroski Score
9.8
Altman Z-Score
What Is Smart Money Doing with AVBP?
Insider Signal
NEUTRAL
0 buys / 1 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
MEDIUM
Signal: NEUTRAL
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →AVBP Growth Story
Revenue YoY
N/A%
3yr Revenue CAGR
N/A%
EPS Growth YoY
-68.75%
FCF Growth YoY
N/A%
Revenue Trend
UNKNOWN
Dark Pool Trades for AVBP
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for AVBP, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 21:01:04 | $13.51 | 2,676 | $$36K | SELL |
| 21:00:39 | $13.51 | 2,765 | $$37K | SELL |
| 21:00:39 | $13.51 | 1,493 | $$20K | SELL |
| 21:00:38 | $13.51 | 2,969 | $$40K | SELL |
| 20:45:50 | $13.51 | 1,800 | $$24K | MIDPOINT |
5 dark pool trades shown · $$158K preview volume
Real-time institutional flow, block trades, and net positioning
Options Flow for AVBP
PREVIEWSEPT Investing provides real-time options flow tracking for AVBP, including unusual sweep detection, block trades, and dealer positioning. Each trade shows strike, expiry, premium, implied volatility, and greek values for informed decision-making.
| Type | Strike | Expiry | DTE | Premium | Size | Trade |
|---|---|---|---|---|---|---|
| CALL | $17.5 | Nov 20 | 9 | $$3800 | 190 | BLOCK |
| CALL | $20 | Nov 20 | 9 | $$500 | 100 | BLOCK |
2 options trades shown · 100% calls
Unusual activity, GEX levels, max pain, and dealer positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for ArriVent BioPharma, Inc. (AVBP) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (3 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →AVBP — frequently asked questions
What is AVBP stock price today?
ArriVent BioPharma, Inc. (AVBP) is at $13.51, up 0.11% (+$0.02) at the Nov 11, 2026 close.
Why is AVBP stock moving today?
Latest AVBP news — Nov 11, 2026: Truist Securities raises ArriVent BioPharma price target · Nov 10, 2026: Truist Securities keeps Buy rating on ArriVent BioPharma, lifts target to $24
What is the AVBP price target?
The average analyst price target for AVBP is $29.00, ranging from $18 to $30, based on 7 analysts. Latest: Guggenheim raises on Oct 28, 2026.
What do analysts rate AVBP?
Analyst ratings for AVBP: 0 Buy, 16 Hold, 0 Sell — consensus Hold.
Did AVBP beat earnings?
AVBP last reported on Aug 12, 2026: EPS -$1.05 vs -$0.99 expected — a miss of 6.4%.
Does AVBP pay a dividend?
AVBP does not currently pay a dividend.
What are AVBP support and resistance levels?
Support: $12.00. Resistance: $15.26, $17.76, $21.23.
What are insiders doing with AVBP?
Insider activity: NEUTRAL, 0 buys and 1 sells in the last 90 days.
What is the latest news on AVBP?
Nov 11, 2026: Truist Securities raises ArriVent BioPharma price target · Nov 10, 2026: Truist Securities keeps Buy rating on ArriVent BioPharma, lifts target to $24 · Nov 9, 2026: ArriVent BioPharma posts Q3 2026 financials